Bosutinib

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Asciminib Roll-over Study

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule

Safety And Efficacy Of Bosutinib

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland

Bosutinib in Elderly Chronic Myeloid Leukemia

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors